Read more at Pharsight press release."The Food and Drug Administration's Critical Path Initiative calls for more PK/PD modeling to streamline drug development and approval," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "As a result, our pharmaceutical and biotechnology clients must find more productive modeling tools.
The graphical and intuitive interface covered by our patent, which we have implemented in Pharsight Trial Simulator, allows them to achieve increased modeling productivity. This means better models, faster learning and improved utilization of scarce modeling personnel."
.jpg)
Comment Preview